Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

Phase 3 Completed 482 enrolled GlaxoSmithKline

RandomizedParallel-groupDouble-blindPrevention

Summary

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Timeline

Start: 2006-03
Primary completion: 2006-07
Completion: 2006-07

Publications

Background Altorjay A, Melson T, Chinachoit T, Kett A, Aqua K, Levin J, Blackburn LM, Lane S, Pergolizzi JV Jr. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg. 2011 Feb;146(2):201-6. doi: 10.1001/archsurg.2010.327.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Casopitant	Small molecule	50 mg	Oral

Indications

No indication recorded.